The cerebral vasculature ensures proper cerebral function by transporting oxygen, nutrients, and other substances to the brain. Distribution of oxygenated blood throughout the neuroaxis takes place at the level of the circle of Willis (CW). While morphologic and functional alterations in CW arteries and its main branches have been reported in cerebrovascular and neurodegenerative diseases, accompanying changes in protein expression profiles remain largely uncharacterized. In this study, we performed proteomics to compile a novel list of proteins present in mouse CW arteries and its ramifications. Circle of Willis arteries were surgically removed from 6-month-old wild-type mice, proteins extracted and analyzed by two proteomics approaches, gel-free nanoLC-mass spectrometry (MS)/MS and gel-based GelLC-MS/MS, using nanoAcquity UPLC coupled with ESI-LTQ Orbitrap XL. The two approaches helped maximize arterial proteome coverage. Six biologic and two technical replicates were performed. In all, 2,188 proteins with at least 2 unique high-scoring peptides were identified (6,630 proteins total). Proteins were classified according to vasoactivity, blood-brain barrier specificity, tight junction and adhesion molecules, membrane transporters/channels, and extracellular matrix/basal lamina proteins. Furthermore, we compared the identified CW arterial proteome with the published brain microvascular proteome. Our database provides a vital resource for the study of CW cerebral arterial protein expression profiles in health and disease.
INTRODUCTION
A healthy cerebral circulation is essential for maintaining brain perfusion and function. 1 In human, oxygenated blood to the brain is delivered by the internal carotid and vertebrobasilar arteries, and is distributed throughout the neuroaxis at the level of the circle of Willis (CW), a ringlike arterial structure located in the subarachnoid space at the base of the brain. The CW is formed by the confluence of the anastomotic branches of the two internal carotid arteries, rostral portion of the vertebrobasilar artery, and the anterior and posterior communicating arteries. 2 The arterial wreath allows for communications between the anterior and posterior circulations providing blood to the forebrain and the hindbrain, respectively, and insures redundancies in the cerebral circulation. 3 The three principal brain arteries arising from the CW are the left and right anterior, middle, and posterior cerebral arteries, cortical branches of which penetrate the brain parenchyma to irrigate the cerebral cortex and deep structures of the brain. 2 In mice, the CW is similarly located along the ventral aspect of the brain extending from the pons-midbrain junction to the anterior cerebrum and involves the same major arteries. 4 Several studies have reported morphologic and protein expression changes in the CW and its surface branches in healthy aging 5 as well as pathologic conditions, such as cerebrovascular and neurodegenerative diseases (e.g., Alzheimer's disease). 5, 6 Arterial wall thickening, loss of elasticity, and alterations in perivascular innervation are common changes observed in aged cerebral arteries. 5 Pathology-associated alterations observed in brain arteries/arterioles resemble an admix of accelerated vascular aging and disease-specific hallmarks, such as amyloid deposits in Alzheimer's disease. To date, in comparison with the plethora of structural and functional changes documented in CW arteries of human and animal models, only a limited number of differentially expressed proteins have been identified. The main aim of our study was to generate, and compile a database of the mouse CW arterial proteome that will provide a valuable resource to study differential protein expression patterns in healthy and diseased brain arteries. In this paper, we have developed methodologies for efficient, mass spectrometry (MS)-compatible arterial protein extraction and peptide detection, and compared the CW arterial proteome with a previously published 7 brain microvascular proteome.
MATERIALS AND METHODS Mice
Eighteen 6-month-old C57BL/6J wild-type (WT) mice from two different breedings (B1 and B2) of nine mice each were used in this study. Furthermore, two 6-month-old WT mice from a third breeding were used for protein validation. To eliminate potential gender-related differences in brain vasculature only males were used. Mice were housed under a 12-hour light-dark cycle, in a temperature (231C) and humidity (50%) controlled room, with food and tap water available ad libitum. All experiments were performed in compliance with the Animal Ethics Committee of the Montreal Neurological Institute and the Canadian Council on Animal Care guidelines.
Surgical Extraction of Circle of Willis Cerebral Arteries
Mice were anesthetized (65 mg/kg sodium pentobarbital, intraperitoneal) and transcardially perfused (0.9% saline, 41C) for 5 minutes to clear the brain vasculature of blood contaminants. After each perfusion, brain was extracted, immersed in a precooled (41C) plexiglass-dissection bath containing 0.9% saline, and secured (ventral side up first) with two pins to the transparent silicone cushion at the bottom of the bath. The CW, cerebral arteries (anterior, middle, and posterior), and their main ramifications were surgically removed from the pia mater under a dissecting microscope. Thereafter, isolated arteries underwent a second round of attached pia mater removal. Similarly prepared 'pure' cerebral arteries from three mice were combined (constituted one biologic replicate) and stored at À 801C. A total of six (B1a, B1b, B1c, B2a, B2b, and B2c) biologic replicates were prepared for this study.
Protein Extraction from Circle of Willis Arteries
Proteins were extracted from surgically isolated arteries using Rapigest SF (Waters, Milford, MA, USA), a MS-compatible acid-labile surfactant that enhances solubilization and tryptic digestion efficiencies of proteins in complex biologic mixtures. 8 To each surgically isolated sample, we added 100 mL of 0.2% (w/v) Rapigest SF in 50 mmol/L ammonium bicarbonate. The mixture was then exposed to three 20-second pulses of sonication (550 Sonic Dismembrator; Fisher Scientific, Ottawa, ON, Canada) to further facilitate protein extraction. The above steps were all performed on ice. After sonication, each preparation was incubated at 951C for 10 minutes, followed by a 20-minute centrifugation (Eppendorf Centrifuge 5415D; Brinkmann Instruments, Westbury, NY, USA) at 10,000 g. The supernatant (S 0 ), containing soluble proteins, was transferred to a fresh tube and used as follows: 5 mL for protein concentration measurement (using Bradford assay; Bio-Rad Corporation, Philadelphia, PA, USA), 80 mL for gel-free proteomics (strong cation exchange (SCX)-LC-MS/MS), and the remaining for gel-based (GelLC-MS/MS) proteomics (see below). The pellet, however, was collagenase treated to recover unextracted/insoluble proteins. Collagenase treatment alters the structure of the collagen fiber network within the arterial wall, 9 loosening the extracellular matrix (ECM) and promoting protein solubility. Each pellet was resuspended in 50 mL of buffered collagenase (0.1 mg/mL crude collagenase, 50 mmol/L Tris, pH 7.5, 2 mmol/L CaCl 2 ) and incubated for 60 minutes at 371C. As crude collagenase also contains active proteases, these samples could only be used for gel-free analysis and not gel-based methods (as the latter requires proteins to be intact). Thus, the collagenase-treated sample was mixed back with 80 mL of its saved S 0 fraction, and the entire mixture sonicated three times (30 seconds each), followed by a 10-minute 951C incubation in a dry bath. Thereafter, the mixture was centrifuged at 10,000 g for 20 minutes to remove debris and the supernatant (S 1 ) collected for gel-free proteomics using ion exchange separation (see below). A total of six biologic replicates were collected for gel-free analysis.
Proteomics Methods for Analyses of Cerebrovascular Proteins
We used two different approaches, gel-based and gel-free, to maximize CW arterial proteome coverage. Both approaches reduced sample complexity by fractionating either (1) at the level of the protein or (2) at the peptide level, respectively. It should be noted that while all six biologic replicates underwent gel-free proteomics, only three samples (B1a, B1b, and B1c) were additionally subjected to the gel-based method.
Gel-based approach (GelLC-MS/MS). Each soluble protein extract S 0 was separated on a 12% one-dimensional SDS-PAGE. A gel cutter was used to consistently cut each sample lane into 29 contiguous pieces and allocated to 10 fractions. Each fraction was allotted 3 contiguous gel pieces, except for fractions 1 and 10. Fraction 1 containing the highest molecular weight proteins was assigned the top two contiguous gel pieces, while fraction 10 containing the lowest molecular weight proteins was apportioned the four contiguous pieces at the bottom of the gel. Each fraction was subjected to in-gel tryptic digestion, and the tryptic peptides were analyzed by nanoLC-MS/MS.
Gel-free approach (strong cation exchange-LC-MS/MS). This approach involved protein deglycosylation and digestion followed by SCX-based separation of peptides. The proteins from soluble and collagenasedigested extracts (i.e., S1) were first denatured (10 minutes at 951C in 100 mmol/L 2-mercaptoethanol) and then deglycosylated using N-Glycosidase F (Roche; Cat. # 11365185001, Laval, QC, Canada) at 371C overnight to increase accessibility to trypsin in later step. Each sample was then reduced in 4 mmol/L dithiothreitol (10 minutes at 951C) followed by alkylation in the dark in 10 mmol/L iodoacetic acid (30 minutes, at room temperature (RT)). Subsequently, each sample was trypsin digested (Trypsin Gold, MS grade, Promega, Madison, WI, USA; Cat. # V5280) by overnight incubation at 371C. The resulting peptides were fractionated by SCX using a protocol described previously. 10 In brief, an ICAT Cation Exchange Cartridge and Buffer Pack (Applied Biosystems, Carlsbad, CA, USA) were used to elute and collect peptide fractions in a stepwise manner, from low to high saltcontaining SCX elution buffer concentration, by slowly injecting (B1 drop/ s) 0.5 mL of each elute buffer. Peptide fractions were collected at 20%, 40%, and 100% elution buffer concentrations. 10 The approach is similar to the MUDPIT methodology used for microvessels, 7 both being gel-free and label-free methods involving strong SCX separation followed by reverse phase nanoLC-MS/MS. However, unlike MUDPIT, our approach involved offline SCX separation.
NanoLC-MS/MS Analysis
For each of the six biologic replicates, each SCX and/or in-gel-digest fraction was analyzed twice (technical replicates) by nanoLC-MS/MS. This culminated to a total of 96 nanoLC-MS/MS runs. In detail, each fraction was analyzed using ESI-LTQ-Orbitrap-XL mass spectrometer (Thermo) coupled to a NanoAcquity UPLC system (Waters). Samples were loaded on a NanoAcquity symmetry C18 trap (Waters) and separated on a 10 cm Â 100 mm I.D. C18 column (Waters, 1.7 mm BEH130C18) at 250 nL/min using a 68minutes gradient: 0% to 45% solution B (100% ACN/0.1% formic acid) over 66 minutes and 45% to 95% solution B over 2 minutes. Ten-minute washes in 40% solution B were followed by 30 minutes blank gradients between each sample to minimize carryover effects. The mass spectrometer was set to automated MS/MS analysis with an MS scan at 60 k resolution in the Orbitrap analyzer and data-dependent turbo MS/MS scans on the top three ions in the trap with dynamic exclusion (180 seconds).
Protein Identification and Bioinformatics
The raw data generated from LTQ-Orbitrap were converted to mzXML format using ReAdW program (http://tools.proteomecenter.org). MGF files were then generated from the mzXML file using MzXML2Search from the Trans Proteomics Pipeline project (http://tools.proteomecenter.org) and the resulting MS/MS spectra were searched against Mus musculus Swiss-Prot database using Mascot v2.2.0 (Matrix Science, Boston, MA, USA) search engine for protein identification with the following parameters: enzyme ¼ trypsin; modifications ¼ carbamidomethyl (C, fixed), oxidation (M, variable); peptide tolerance ¼ 1.5 Da; fragment tolerance ¼ 1.5 Da; 1 missed cleavage allowed). Decoy database searches were used to estimate the false positive identification rate. Search results were subsequently filtered to remove peptides with a delta mass of 415 p.p.m. or a score of o35. Under these conditions, the false positive identification rate based on decoy database searches was 1%. Peptides with a score of 450 had a false positive rate of 0.2%. As an independent statistical measure of peptide identification, Peptide Prophet probabilities (P scores) were also measured. All identified peptides had P scores X0.95. For proteins identified based on only one peptide, additional peptides corresponding to the same proteins within the same gel band with P scores 40.9 were also examined and reported where indicated. To extract quantitative MS data, align all runs, and integrate protein search results, in-house software MatchRx 10 version QnD-2.0 was used. MatchRx defines peptide peaks, extracts peptide abundance values from LC-MS data, allows quantitative comparison of peptide levels in two or more samples, and overlays the quantitative differences of peptides and LC-MS/MS identification results (from Mascot) into MSight images. 10 Peptide intensity validation was performed using MSight software version 1.0 (http://www.expasy.ch/ MSight), a visualization tool that allows graphical representation of the LC-MS and LC-MS/MS data.
Characterization of Arterial Protein List
Two protein lists (List 1 and List 2) of varying stringency were generated. All proteins with P scores X0.95 were included in List 1. The second, more stringent List 2 only contained proteins identified with at least two peptide hits and P scores X0.95. Subcellular localizations and function of proteins were determined using a combination of Gene Ontology (www.geneontology. org) and the Universal Protein Resource (UniProt, www.uniprot.org) databases. The PANTHER Classification System (www.pantherdb.org) was used to classify proteins into pathways. Only pathways with 42 proteins were accounted. Proteins were classified as endothelial cell (EC) proteins if present in an in-house EC database compiled through proteomics/literature mining, and as vascular smooth muscle cell (SMC) proteins if present in an in-house vascular SMC database compiled via literature mining of cultured arterial SMC proteomics data sets.
Western Blotting
Western blots were performed to validate List 1 proteins discoidin domain receptor tyrosine kinase 2 (DDR2) and hyperpolarization-activated cyclic nucleotide-gated cation channel 2 (HCN2), both known to be present in peripheral but not in cerebral arteries. DDR2 is a collagen receptor implicated in the regulation of SMC-mediated collagen turnover in atherosclerosis. 11 The ion channel HCN2 is suggested to have a role in the control of vascular tone and dysregulation of its expression may contribute to vascular pathology. 12 Frozen CW arteries from each mouse (n ¼ 2) were digested in 35 mL Laemmli buffer. 13 In brief, each preparation was repeatedly exposed to a pulse of vortexing (20 seconds, RT), followed by incubation (10 minutes, RT) for 2 hours. Thereafter, each preparation was incubated (10 minutes, 1001C), centrifuged (2 minutes, RT), and the supernatant retained. In all, 9 mL of the supernatant was loaded in 5% to 10% Tris/tricine SDS-PAGE gradient gels, separated by electrophoresis, and transferred onto nitrocellulose membranes. Membranes were incubated (1.5 hours, RT) in a blocking buffer containing 5% skim milk and then (overnight, 41C) with rabbit anti-HCN2 (1:100; Alomone Labs, Jerusalem, Israel) or -DDR2 (1:150; Abcam, Cambridge, MA, USA). Actin was used as the loading control. Membranes were further incubated (1 hour, RT) with horseradish peroxidase-conjugated secondary antibodies (1:1,500 and 1:1,000, respectively) and proteins visualized by chemiluminescence (ECL plus kit; GE Healthcare) using a phosphorImager (Scanner STORM 860; GE Healthcare, Mississauga, ON, Canada).
Comparison with Microvascular Proteome
List 2 arterial proteins were compared with the previously released cerebral microvessel protein data set. 7 Inclusion criteria used for microvascular proteins were the following: (1) the presence of X2 unique tryptic peptides, (2) the presence of protein in all technical replicates, and in at least one biologic replicate, and (3) an average spectral count of X5. Common and unique proteins to each data set were identified. The PANTHER Classification System was used to classify proteins by pathways. Proteins were listed as (1) blood-brain barrier (BBB)-specific cell type proteins, (2) tight junction (TJ) and adhesion proteins, (3) membrane transporter and channel proteins, and (d) ECM and basal lamina proteins, if they were (1) identified as such in the microvascular proteomics data set, 7 (2) classified accordingly by Gene Ontology or UniProt databases, and were (3) present in either the mouse 14 or rat 15 BBB transcriptome repositories.
RESULTS

Extraction and Solubilization of Cerebral Arteries
The CW and its ramifications ( Figure 1A ) were extracted in a reproducible manner using the surgical procedure described (see Materials and methods). Figure 1B outlines the protein solubilization and digest workflow developed in-house for efficient protein extraction from CW cerebral arteries. On average, 87 mg (ranged from 70 to 110 mg) proteins were extracted per biologic replicate. Figure 1C shows the reproducibility of two technical and biologic replicates, where the median relative standard deviation between technical replicates is 6% and between biologic replicates is 18%, values similar to that published for gel-free analysis. 16 Proteomic Profile A total of 6,630 CW cerebral arterial proteins (List 1 proteins, Supplementary Table 1 ) were identified at P scores X0.95. Of these proteins, 1,911 (28.8%) were detected using gel-based approach only, 2,875 (43.4%) using gel-free approach only, while 1,844 proteins (27.8%) were detected using both methods ( Figure 2A ). The latter was considered as 'common CW cerebral arterial proteins'. Subcellularly, the top five locations List 1 proteins corresponded to membrane (41.3%), cytoplasm (40.1%), nucleus (32.1%), mitochondrion (10.2%), and secreted (8.8%) ( Figure 2C ). In addition, List 1 proteins DDR2 and HCN2 were validated using western blots ( Figure 2D ).
A total of 2,188 List 1 proteins (33%) were identified with X2 peptides each and were cataloged as List 2 proteins (Supplementary Table 1 ). Approximately half (52%) of these were detected using both gel-based and gel-free approaches ( Figure 2B ). The top five subcellular locations of List 2 proteins were cytoplasm (46.3%), membrane (41.7%), nucleus (33.7%), mitochondrion (12.6%), and secreted (8.6%) ( Figure 2C ). A total of 466 proteins (21% of List 2 proteins) belonged to curated pathways in the PANTHER database. Ten pathways with 420 proteins were observed. In descending number of proteins they were as follows: integrin signaling (89 proteins), inflammation mediated by chemokine and cytokine signaling (53 proteins), heterotrimeric G-protein signaling (49 proteins), Wnt signaling (41 proteins), angiogenesis (36 proteins), platelet-derived growth factor signaling (36 proteins), cytoskeletal regulation by Rho GTPase (34 proteins), epidermal growth factor receptor signaling (27 proteins), cadherin signaling (23 proteins), and phosphatidylinositol 3-kinase pathway (23 proteins). 
Vasoactivity
We detected 78 proteins shown to regulate the cerebral circulation or exert vasomotor effects on cerebral arteries (Table 1 ; Supplementary Table 2 for references and additional information). A few of these, specifically, neuronal mediators of vasoactivity and their vascular receptors detected in our arterial data set have been highlighted in the subsections below, and are illustrated in Figure 3 .
Neuronal proteins. Ultrastructural investigations of cerebral arteries show a rich neuronal network at the adventitia-media junction. 17 Originating from the peripheral nervous system, these 'extrinsic' nerve fibers are well-established modulators of vasoactivity. 1 Of the classic vasoactive substances released by these nerves, we detected the pituitary adenylate cyclase-activating polypeptide (ADCYAP1 or PACAP) ( Figure 3 ). We also detected eight other neuronal facilitators of vasomotricity, in particular, neuronal nitric oxide (NO) synthase (NOS1), muscarinic acetylcholine (ACh) receptor M2 (CHRM2), alpha1A subunit of the voltage-dependent P/Q-type calcium channel (CACNA1A), and choline O-acetyltransferase (ChAT) represented in Figure 3 , as well as, tyrosine 3-monooxygenase (or tyrosine hydroxylase, TH), monoamine oxidases type A and B (MAOA, B), and catechol O-methyltransferase domain-containing protein 1 (COMTD1).
Arterial proteins. We also detected receptors, known to be present on the vessel wall, that bind vasoactive molecules released by the extrinsic nerve fibers. These included the a-1A and a-2C adrenergic receptors (ADRA1A and ADRA2C), vasoactive intestinal polypeptide receptor 1 (VIPR1 or VPAC1), neurokinin A receptor (TACR2 or NK2R), and the 5-hydroxytryptamine receptors 2A and 2C (HTR2A and HTR2C) (Table 1; Figure 3 ).
In addition, we detected various smooth muscle and endothelial mediators of vasoactivity (Table 1; Supplementary Table 2 for references and additional information), including endothelial NO synthase (NOS3 or eNOS) that generates NO, a potent vasodilator. A cartoon diagram summarizing how some of Table 1 proteins mediate arterial smooth muscle motricity is presented in Figure 4 .
Cerebral Arterial Versus Microvascular Proteomes
A total of 3,411 unique proteins were present in the arterial (List 2, 2,188 proteins total) and microvascular (1,824 proteins total) data sets combined ( Figure 5A ). Of these, 1,587 (47%) and 1,223 (36%) proteins were unique to the arterial and microvascular data sets, respectively, whereas 601 (18%) were common to both ( Figure 5A ). These common proteins comprised 28% of the List 2 CW cerebral arterial data set and 33% of the microvascular data set. Analysis of common proteins yielded a total of 62 PANTHER pathways, the top 5 being integrin signaling (35 proteins), heterotrimeric G-protein signaling (26 proteins), inflammation mediated by chemokine and cytokine signaling (23 proteins), cytoskeletal regulation by Rho GTPase (17 proteins), and Wnt signaling (13 proteins). A total of 58 pathways were identified for proteins solely present in either arteries or microvessels. Of these, 2 and 7 pathways were unique to arterial and microvascular proteomes, respectively, whereas 49 were common. Listed are data set-specific pathways with X4 proteins: (1) hypoxia response via hypoxia-inducible factor activation pathway (unique to arterial data set) and (2) 5HT4 type receptor mediated signaling pathway, corticotropin releasing factor receptor signaling pathway, opioid (prodynorphin, proenkephalin, and proopiomelanocortin) pathways, b3 adrenergic receptor signaling pathway, and androgen/ estrogen/progesterone biosynthesis pathway (unique to microvascular data set). In the following subsections, we compare protein distributions of (1) smooth muscle and endothelial components and (2) BBB and associated categories in the arterial and microvascular data sets.
Smooth muscle cell and endothelial cell protein distribution. We identified 230 (11%) SMC-and 1,035 (47%) EC-classified proteins uniquely present in the arterial data set containing a total of 2,188 proteins ( Figure 5B ). In all, 204 (9%) of these proteins were common to both cell types. In comparison, we established that 122 (7%) SMCand 623 (34%) EC-classified proteins were unique to the microvascular data set containing a total of 1,824 proteins ( Figure 5B ). In all, 107 (6%) of these proteins were common to both cell types. In addition, we identified 218 SMC-and 515 EC-classified proteins common to both arterial and microvascular data sets (containing a total of 3,411 proteins), with 206 (6%) belonging to both cell types. Blood-brain barrier-specific proteins. In the arterial and microvascular data sets combined, we detected 86 BBB-specific proteins, 28 (33%) of which were detected in both sample types (Table 2; Figure 5C ). While 52 BBB-enriched proteins were microvascular data set specific, we detected only 6 such proteins exclusive to our arterial data set. These included two transporters (ABCB1A and SLC2A1), three transcriptional regulators (EBF1, FOXQ1, and LEF1), and the DNA repair protein RAD54B.
Tight junction and adhesion proteins. We identified 83 TJ and/or adhesion proteins. Of these proteins, 19 and 37 were specific to arteries and microvessels, respectively, while 27 proteins were common to both data sets ( Figure 5D ; Table 2 ). In descending order, common proteins belonged to the following groups: nine TJ plaque proteins: DLG4, MAGI1, MAGI3, MPDZ, MPP1, SYMPK, TJP1, TJP2, and WNK1; six immunoglobulin superfamily cell adhesion molecules (ALCAM, CD44, MCAM, NRCAM, PECAM1, and VCAM1), six integrins (a1, 3, 7, V and b1, 3), and five catenins (a1 and 2, b1, and d1, 2) ( Supplementary Table 3 -for protein function and cellular component details).
Membrane transporter and channel proteins. We detected 138 proteins in the arterial and microvascular data sets involved in transport across the plasma membrane. Sixty-eight of these proteins were present in our arterial data set and include 28 solute carrier proteins (SLCs), 14 adenosine 5 0 -triphosphate (ATP)-binding cassette proteins (ABCs), and 26 ATPases (Na þ /K þ , H þ /K þ , and Ca 2 þ ) ( Table 2 ). Twenty-nine of the above-mentioned proteins were unique to our data set, while thirty-nine were also present in the microvascular data set ( Table 2 ; Figure 5E ). In comparison, a larger number (70) of transporters were found exclusively in microvascular data set ( Figure 5E ).
Extracellular matrix and basal lamina proteins. A total of 94 ECM and/or basal lamina proteins were identified in the two data sets combined ( Figure 5F ). Of these 64 were present in our arterial data set only (Table 2) , while a smaller number (15) were microvascular specific. Fifteen proteins were common to both data sets ( Table 2) . These included six laminins (subunits a2, a4, a5, b2, g1, and g3), two collagens (IVa1 and IVa2), two nidogens (1 and 2), agrin, annexin A2, fibronectin, hyaluronan/proteoglycan link protein 1, and basement membrane-specific heparan sulfate proteoglycan core protein.
DISCUSSION
We have generated the first extensive database of 6,630 proteins expressed in the wall of fresh cerebral arteries. An advantage of using freshly isolated over cultured tissue is that it allows for maximal preservation of the tissue microenvironment experience in vivo in the absence of potential tissue culture-induced artifacts, such as phenotypic drift, that can result in altered protein expression. 18 Of the 6,630 proteins in our database, 33% were detected with X2 peptides at P scores X0.95, and the remaining 67% with at least 1 peptide and the same stringent P scores cutoff. We established that approximately half (56%) of the proteins in our arterial databank are of known vascular origin, being copresent in the EC and/or the vascular SMC protein databases. We further established that almost a third of these proteins are robustly expressed in cerebral arteries and can be detected by both gel-based and gel-free approaches.
Arterial Proteome Coverage
To generate a comprehensive arterial protein database, we developed highly reproducible methodologies that allowed for (1) rapid surgical isolation of fresh cerebral arteries, (2) efficient protein extraction using the MS-compatible surfactant Rapigest, with yields B3 Â higher compared with SDS-based extraction (unpublished data), and (3) optimal detection and quantification of low-abundant peptides. Concomitant use of gel-based and gelfree approaches contributed to increased detection of peptides (and proteins) as showcased by (1) the presence of EC layer proteins, which are harder to detect since unlike the SMC and adventitia layers, the EC layer is a single layer of cells and (2) good agreement between the breakdown of detected arterial proteins by subcellular localization and the relative sizes of cellular compartments (e.g., membrane4mitochondria).
Cerebral Arteries and Vasoactivity
Large arteries as well as smaller arterioles at the brain surface constitute resistance vessels that control blood flow and influence global perfusion. 5 Vascular resistance is essential for pushing blood through the cerebral circulation, and is increased through contraction of the vessel muscular wall, and decreased via vasodilation stemming from the relaxation of SMCs. 5 Interestingly, 3 of the top 10 PANTHER pathways detected in our arterial data set, namely heterotrimeric G-proteins (e.g., Figure 4 ), integrin signaling (e.g., Figure 4 ), and cytoskeletal regulation by Rho GTPases, are established modulators of vasomotricity. [19] [20] [21] In addition to signaling cascade proteins, we also identified several perivascular and vascular mediators of vasoactivity that are discussed in the following two sections.
Neuronally released vasoactive substances and their receptors. Nerve fibers originating in the peripheral nervous system, specifically, the superior cervical ganglion (sympathetic innervation), the sphenopalatine and otic ganglia (parasympathetic innervation), and the trigeminal ganglion exert vasomotor control on cerebral arteries via release of neurotransmitters and other vasoactive substances. 1 We detected vascular receptors for five of these substances in our arterial data set, in particular, the a-1A and a-2C adrenergic receptors (ADRA1A and ADRA2C); the neuropeptide Y receptor, NPY6R; serotonin receptors, HTR2A (or 5-HT2A) and HTR2C (or 5-HT2C); the established vasoactive intestinal polypeptide receptor, VIPR1 (or VPAC1); the lesser known intestinal polypeptide receptor, NPR3 (or NPRC (natriuretic peptide receptor C)); and finally, the neurokinin A receptor TACR2 (or NKR2) ( Figure 3) . The presence of all abovementioned receptors, with the exception of NPY6R and HTR2C, has been previously shown in cerebral arteries (for references, see Supplementary Table 2 ). Moreover, the detected receptors are G protein-coupled and modulate vasoactivity via heterotrimeric G-protein signaling, interestingly, a top 10 PANTHER pathway detected in our study. We also detected nine neuronal mediators of vasoactivity (Table 1 ; Supplementary Table 2 for references; and Figure 3 ). Of these, the pituitary adenylate cyclase activating peptide (ADCYAP1 or PACAP), released by perivascular nerve fibers originating in the trigeminal ganglion, is an established vasodilator. 22 The calcium channel CACNA1A facilitates release of the calcitonin gene-related protein, 23 another vasodilator compound released by trigeminal ganglion originating nerves. 1 The presynaptic muscarinic ACh receptor CHRM2 (or mAChR2), located on ACh releasing nitric oxidergic nerves originating in sphenopalatine and otic ganglia, is known to mediate inhibition of neurogenic vasodilation in cerebral arteries via reduction in NOS activity and the production and release of the vasodilator NO. 24 Both ChAT and NOS1 (or nNOS) enzymes involved in the synthesis of ACh and NO, respectively, were present in our arterial data set. In addition, we detected four enzymes (TH, MAOA, MAOB, and COMTD1) involved in the formation and degradation of superior cervical ganglion released vasoactive substance, norepinephrine (or noradrenaline). 25 Proteins involved in vascular smooth muscle contractility and relaxation. Among the key effectors of smooth muscle contraction we detected calmodulin (CALM1), the 20-kDa myosin light chain (MYL12B or LC20), as well as the myosin light chain-specific kinase (MYLK or MLCK) and phosphatase (PPP1 or MLCP). Both catalytic (PPP1CA, B, and C) and myosin-targeting (PPP1R12A, B, and C) subunits of the phosphatase were detected, with only PPP1R12A previously reported in cerebral arteries (Supplementary Table 2 for references). It is well established that intracellular-free calcium (iCa 2 þ ) binds with calmodulin, which then binds and activates the myosin light-chain kinase. 19 The activated kinase complex then phosphorylates myosin on the 20-kDa light chains, resulting in smooth muscle contraction. 19 Conversely, dephosphorylation of myosin light chains induces relaxation (Figure 4 ). Activated protein kinase C (PKC) and integrins are known to inhibit dephosphorylation under physiologic conditions via the PKCpotentiated inhibitory protein of MLCP (PPP1R14A) and the integrin linked kinase, respectively 20 (Figure 4 ). We detected two classic PKCs (PRKCA and PRKCG), PPP1R14A and integrin linked kinase in our arterial data set, with all except for PRKCG previously reported in cerebral arteries (Supplementary Table 2 for references), as well as several integrins (see Table 2 ).
Increases in iCa 2 þ are a major determinant of arterial smooth muscle contractility. 19 In SMCs, rise in iCa 2 þ is facilitated by (1) Ca 2 þ release from intracellular stores in the smooth sarcoplasmic reticulum and (2) Ca 2 þ entry from the extracellular space via plasma membrane Ca 2 þ channels (Figure 4 ). Ca 2 þ release from sarcoplasmic reticulum requires hydrolysis of plasma membrane phosphatidylinositol 4,5-bisphosphate by phospholipase C (PLC). 21 We detected five PLC isozymes belonging to b (B1, 3), e (E1), and Z (H1, 2) subtypes, of which, PLC-b, and -e are activated by agonist (including vasoactive substances) binding to plasma membrane G protein-coupled receptors. 21 All PLC isozymes detected are known generators of second messengers, inositol 1,4,5-trisphosphate (IP3) and 1,2-diacylglycerol. 21 Binding of IP3 to sarcoplasmic reticulum surface receptors (IP3Rs or ITPRs) activates Ca 2 þ release. 26 We detected three ITPRs, namely ITPR1, 2, and 3, all previously showed to be present in rat cerebral artery SMCs with ITPR1 being the most abundant. 27 In addition, the second messenger 1,2-diacylglycerol has been shown to activate PKC, which in turn increases smooth muscle contractility via several different mechanisms such as MLCP inhibition and increased actin availability. 20 Several pathways of Ca 2 þ entry from the extracellular space have been suggested, and include passive leak Ca 2 þ channels, as well as channels activated by membrane depolarization (voltage gated), agonist binding (receptor operated), depletion of Ca 2 þ from intracellular stores (store operated), or stretch. 28 Voltagegated Ca 2 þ channels enriched in SMCs of major cerebral arteries and arterioles are of L, and to a lesser extent, T type. 29 We detected four a-1 subunits belonging either to the high-voltageactivated L-type (CACNA1C, D, and F) or to the low-voltageactivated T-type (CACNA1H) channels. Of these, mRNAs of CACNA1C (or Cav1.2) and CACNA1H (or Cav3.2) have been previously detected in rat cerebral artery SMC and mouse coronary artery, respectively (Supplementary Table 2 for references). We also detected a known b subunit isoform (CACNB1) of the L-type channel. Interestingly, the a1-subunit forms the ion-conducting pore of voltage-gated Ca 2 þ channels, while the b subunit is involved in the modulation of gating. 30 Receptor-operated Ca 2 þ channels frequently detected in SMC plasmalemma belong to the P2X purinoreceptor family and activate upon binding of extracellular ATP. 28, 31 Of these, we detected the P2RX7 receptor, expression of which has been previously shown in cerebral arteries (Supplementary Table 2 for references). In addition, emerging evidence suggests relatedness between receptor-and store-operated Ca 2 þ channel types, both being formed by proteins of the transient receptor potential channel (TRPC) family. 32 We identified six proteins (TRPC1, 2, 4, 5, 6, and 7) belonging to this family, all of which can form Ca 2 þ permeable cation channels, and except for TRPC2 have been previously shown to be present in cerebral arteries (Supplementary Table 2 for references). Mechanical stretch-induced Ca 2 þ influx is known to occur via opening of nonspecific cation channels in SMC membranes. We detected one such channel, specifically, the transient receptor potential cation channel TRPM4, an inherently mechanosensitive channel 33 shown to be present in cerebral arterial myocytes.
In contrast to smooth muscle contraction, its relaxation is accompanied by a decrease in iCa 2 þ levels to resting values. Decrease in iCa 2 þ is facilitated by (1) reuptake into intracellular stores by Ca 2 þ ATPase pumps (smooth endoplasmic reticulum calcium ATPases, SERCAs) on the sarcoplasmic reticulum membrane and (2) extrusion from the cell by the plasma membrane Ca 2 þ ATPases (PMCAs) and the Na þ /Ca 2 þ exchanger (Figure 4 ). We detected three SERCAs (ATP2A1, A2, and A3), one PMCA (ATP2B2), and one Na þ /Ca 2 þ exchanger (SLC8A1 or NCX) in our arterial data set. To date, only mRNAs of ATP2B2 and SLC8A1 have been reported in cerebral arteries (Supplementary Table 2 for references). The SMC relaxation is further promoted by the activation of multiple arterial smooth muscle potassium (K þ ) channels. These channels provide an opposing hyperpolarizing influence reducing Ca 2 þ channel activity. We detected multiple K þ channels in our arterial data set, in particular, large (KCNMA1 or BKCa), intermediate (KCNN4), and small (KCNN2 or SKCa) conductance Ca 2 þ -activated K þ channels, as well as ATPsensitive (KATP channel subunits KCNJ8 and 15), and voltageactivated K þ channels (KCNA3, A5-7, C2, H5 and H8, Q1-5, V2, AB1 and AB3). The majority of these K þ channels have been previously observed in cerebral arteries (Supplementary Table 2 for references). Particularly, the peptide calcitonin gene-related peptide potently dilates brain cerebral arteries through activation of SMC K þ channels. 34 Each of the endotheliumderived relaxing factors, namely NO, prostacyclin, and endothelium-derived hyperpolarizing factor, can activate one or several types of SMC K þ channels. 35 We detected three NOSs in our arterial data set, specifically the previously mentioned NOS1 (or nNOS), as well as NOS2 (or iNOS) and NOS3 (or eNOS).
Insights into the Proteomes of Arteries and Microvessels
The recent release of the cerebral microvessel proteomics study 7 provided an opportunity to compare and contrast protein-based findings in pial/extracerebral CW arteries (this study) and intraparenchymal brain vessels. Vessel diameters in our sampling of mouse cerebral arteries were B100 mm and lower, with the majority being large diameter vessels. The wide range of arterial diameters in our sampling is representative of the varied vessel sizes present at the brain surface, starting with the CW and its major arteries ranging from 75 to 100 mm in diameter. 36 Furthermore, it has been shown that peripheral branches of the major arteries range between 50 and 70 mm in diameter, while their ramifications coursing over the brain surface, reach 35 mm or lower in diameter, just before perforating as penetrating intracerebral arterioles. 36, 37 In comparison with our arterial sample, vessel diameters in the microvascular sampling 7 ranged between 420 mm and o100 mm. Thus, it can be concluded that while the majority of vessels in the microvascular sample tended toward small diameters, some overlap in vessel diameter size exists between the two studies.
Comparatively, the most striking difference between the arterial and microvascular data sets was the B9 Â increase in the number of unique BBB-specific cell types in the latter. Disparities in unique protein numbers in 'TJ and adhesion proteins' and 'membrane transporter and channel proteins' categories, while lesser (B2x more in the microvascular data set), were still present. Overall, our findings of protein number inequalities in the above-mentioned categories are in line with the knowledge that at the level of cerebral arteries, the BBB is not as developed, nor specialized, as in intracortical microvessels. Incomplete barrier characteristic of cerebral arteries has been shown in smaller diameter surface vessels using endothelial barrier antigen staining. 38 Compared with the uniform staining present in intracortical microvessels, those on the cerebral surface showed heterogeneity in endothelial barrier antigen expression. 38 Moreover, two populations of interendothelial TJs have been shown in these surface microvessels, (1) those with the BBB-type fusion of adjacent membranes and (2) those with discernible gap between them. 39 Unlike the three above-mentioned protein categories, the arterial data set housed higher numbers (B5 Â ) of 'ECM and basal lamina proteins' compared with intracortical microvessels, probably as a consequence of an adventitia layer present in the former. This layer, largely composed of ECM proteins, is absent in intracortical microvessels. 40 In summary, we have compiled a novel resource database for proteins present in the arterial wall of mouse CW and its surface ramifications. To ensure detection and identification of an extensive and comprehensive list of CW cerebral arterial proteins, we used fresh unfixed tissue and employed two parallel, custom proteomic approaches. Our database provides an excellent resource for the study of protein expression profile in healthy cerebral arteries and its perturbations in cerebrovascular diseases. Furthermore, we shed light on the difference and the similarities between brain arteries and microvessels at the level of the proteome.
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